A Scalable Platform for Biomarker-Led Insight
From a Single Assay to a Biomarker Platform
FAST>ER™ represents the first clinical application of a broader biomarker platform designed to support objective molecular insight across multiple clinical contexts.
The platform approach enables disciplined expansion into additional applications where biomarker signals may provide meaningful context, guided by scientific evidence and biological relevance.
Platform Philosophy
The biomarker platform is built around a core set of principles:
- Biological relevance first
- Evidence-driven expansion
- Reuse of validated assay architecture
- Clear separation between clinical use and exploratory research
Each application is evaluated independently to ensure scientific integrity and appropriate interpretation.
Core Platform Components
The platform integrates several foundational elements:
- Biomarker targets selected for biological relevance
- Immunoassay architecture optimized for point-of-care use
- Analytical tools to support interpretation
- Workflow-compatible formats adaptable across settings
This modular structure supports consistency while allowing application-specific refinement.
Initial Application Focus
The platform’s initial focus centers on time-critical care environments, where early molecular insight may complement existing clinical assessment tools.
Current areas of focus include:
- Acute neurologic injury
- Ischemic injury
- High-acuity clinical decision settings
These contexts emphasize speed, objectivity, and integration into established workflows.
Expanding the Platform
Beyond initial applications, the platform supports exploration of additional clinical and translational areas where biomarker information may be relevant.
Areas under evaluation include:
- Neurodegeneration and chronic injury
- Oncology-related stratification and monitoring
- Neonatal and perinatal injury
- Veterinary and animal health applications
Each area is explored incrementally, guided by biological rationale and supporting data.
Veterinary & Animal Health
The platform architecture is adaptable to non-human applications, including animal health contexts where rapid, on-site biomarker assessment may be valuable.
Potential areas include:
- Disease monitoring
- Injury-related biomarker assessment
- Field-deployable testing environments
Animal health applications are developed independently and tailored to their specific use environments.
A Disciplined Path to Expansion
Platform expansion follows a structured scientific process:
- Biological relevance and rationale
- Feasibility within the assay architecture
- Analytical evaluation
- Clinical or translational study
- Evidence-based refinement
This approach ensures that growth of the platform remains grounded in data and scientific responsibility.
Platform at a Glance
- Modular biomarker-based architecture
- Reusable assay foundation
- Evidence-driven expansion
- Independent evaluation per application
- Applicability across human and animal health
Disclaimer
Platform applications beyond the initial focus are under evaluation and development. Scientific status and intended applications may vary by context.